News · 19 November 2026

Hims & Hers starts selling unapproved peptide treatments

19 November 2026 · Health · US · Business

Hims & Hers starts selling unapproved peptide treatments
Picture: CNBC Business · CNBC Business lead image · unknown

The telehealth company will offer five compounded products, including sermorelin, glutathione and NAD+. None of its versions are approved by the FDA. More than 10,000 people joined the waitlist in 15 days. Its chief medical officer says there is still a lot to learn about how well they work.

Where this came from. One outlet reported this. We read it, then wrote the sixty words above.

Also on 19 November 2026